T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency vires-infected patients with sustained viral suppression during antiretroviral therapy

Journal of Infectious Diseases

Volumn 187, Issue 10, 2003, Pages 1534-1543

  Hunt, Peter W ^a,d   Martin, Jeffrey N ^a,c   Sinclair, Elizabeth ^b   Bredt, Barry ^b   Hagos, Elilta ^a   Lampiris, Harry ^a   Deeks, Steven G ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CD8 ANTIGEN; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ADULT; ARTICLE; COMORBIDITY; CORRELATION ANALYSIS; FEMALE; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOPHENOTYPING; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; VIREMIA; VIRUS VIRULENCE;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; RNA, VIRAL;

EID: 0038701685     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/374786     Document Type: Article

References (60)

1. Detels R, Munoz A, McFarlane G, et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. JAMA 1998; 280:1497-503.
2. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-60.
3. Kaufmann GR, Bloch M, Finlayson R, et al. The extent of HIV-1-related immunodeficiency and age predict the long-term CD4 T lymphocyte response to potent antiretroviral therapy. AIDS 2002; 16: 359-67.
4. Valdez H, Connick E, Smith KY, et al. Limited immune restoration after 3 years' suppression of HIV-1 replication in patients with moderately advanced disease. AIDS 2002; 16:1859-66.
5. + cell kinetic patterns and their relationships with baseline factors and virological responses in HIV type 1 patients receiving highly active antiretroviral therapy. AIDS Res Hum Retroviruses 2001; 17:1231-40.
6. Lederman MM, McKinnis R, Kelleher D, et al. Cellular restoration in HIV infected persons treated with abacavir and a protease inhibitor: age inversely predicts naive CD4 cell count increase. AIDS 2000; 14: 2635-42.
7. Viard J-P, Mocroft A, Chiesi A, et al. Influence of age on CD4 cell recovery in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy: evidence from the EuroSIDA study. J Infect Dis 2001; 183:1290-4.
8. Smith KY, Valdez H, Landay A, et al. Thymic size and lymphocyte restoration in patients with human immunodeficiency virus infection after 48 weeks of zidovudine, lamivudine, and ritonavir therapy. ACTG 375 Protocol Team. J Infect Dis 2000; 181:141-7.
9. Teixeira L, Valdez H, McCune JM, et al. Poor CD4 T cell restoration after suppression of HIV-1 replication may reflect lower thymic function. AIDS 2001; 15:1749-56.
10. + T cells in HIV-1-infected patients. AIDS 1996; 10:827-34.
11. + T cells is a marker of poor prognosis in HIV infection: results of 6 years of follow-up. Cytometry 1996; 26:1-7.
12. Giorgi JV, Hultin LE, McKeating JA, et al. Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis 1999; 179:859-70.
13. Mahalingam M, Peakman M, Davies ET, et al. T cell activation and disease severity in HIV infection. Clin Exp Immunol 1993; 93:337-43.
14. Hellerstein M, Hanley MB, Cesar D, et al. Directly measured kinetics of circulating T lymphocytes in normal and HIV-1-infected humans. Nat Med 1999; 5:83-9.
15. + T cell kinetics and activation in human immunodeficiency virus-infected patients who remain viremic despite long-term treatment with protease inhibitor-based therapy. J Infect Dis 2002; 185:315-23.
16. McCune JM, Hanley MB, Cesar D, et al. Factors influencing T-cell turnover in HIV-1-seropositive patients. J Clin Invest 2000; 105:R1-8.
17. Gougeon ML, Lecoeur H, Dulioust A, et al. Programmed cell death in peripheral lymphocytes from HIV-infected persons: increased susceptibility to apoptosis of CD4 and CD8 T cells correlates with lymphocyte activation and with disease progression. J Immunol 1996; 156: 3509-20.
18. + T cells is markedly enhanced in the setting of antigen-specific immune activation. J Exp Med 1996; 183:687-92.
19. Shattock RJ, Rizzardi GP, Hayes P, Griffin GE. Engagement of adhesion molecules (CD18, CD11a, CD45, CD44, and CD58) enhances human immunodeficiency virus type 1 replication in monocytic cells through a tumor necrosis factor-modulated pathway. J Infect Dis 1996; 174:54-62.
20. Bleul CC, Wu L, Hoxie JA, et al. The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes. Proc Natl Acad Sci USA 1997;94:1925-30.
21. Ostrowski MA, Justement SJ, Catanzaro A, et al. Expression of chemokine receptors CXCR4 and CCR5 in HIV-1-infected and uninfected individuals. J Immunol 1998; 161:3195-201.
22. Wu L, Paxton WA, Kassam N, et al. CCR5 levels and expression pattern correlate with infectability by macrophage-tropic HIV-1, in vitro. J Exp Med 1997; 185:1681-91.
23. Kinoshita S, Chen BK, Kaneshima H, et al. Host control of HIV-1 parasitism in T cells by the nuclear factor of activated T cells. Cell 1998; 95:595-604.
24. Perkins ND, Edwards NL, Duckett CS, et al. A cooperative interaction between NF-kappa B and Sp1 is required for HIV-1 enhancer activation. Embo J 1993; 12:3551-8.
25. Antoni BA, Stein SB, Rabson AB. Regulation of human immunodeficiency virus infection: implications for pathogenesis. Adv Virus Res 1994; 43:53-145.
26. Grossman Z, Feinberg MB, Paul WE. Multiple modes of cellular activation and virus transmission in HIV infection: a role for chronically and latently infected cells in sustaining viral replication. Proc Natl Acad Sci USA 1998; 95:6314-9.
27. Hazenberg MD, Otto SA, Cohen Stuart JW, et al. Increased cell division but not thymic dysfunction rapidly affects the T-cell receptor excision circle content of the naive T cell population in HIV-1 infection. Nat Med 2000; 6:1036-42.
28. + T cells go out of stock. Nat Immunol 2000; 1:285-9.
29. + T-cell activation in HIV infection is antigenic stimulation. J Acquir Immune Defic Syndr 2000; 25:203-11.
30. + T-cell depletion in HIV infection: are we closer to understanding the cause? Nat Med 2002; 8:319-23.
31. Havlir DV, Bassett R, Levitan D, et al. Prevalence and predictive value of intermittent viremia with combination HIV therapy. JAMA 2001; 286:171-9.
32. Department of Health and Human Services and Kaiser Family Foundation guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Rockville, MD: AIDSinfo, 2002.
33. Yeni PG, Hammer SM, Carpenter CC, et al. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society - USA Panel. JAMA 2002; 288:222-35.
34. + lymphocytes after HIV antiretroviral therapy reflects redistribution from lymphoid tissues. J Clin Invest 1999; 103:1391-8.
35. Pakker NG, Notermans DW, de Boer RJ, et al. Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation. Nat Med 1998; 4:208-14.
36. Sousa AE, Chaves AF, Doroana M, et al. Kinetics of the changes of lymphocyte subsets defined by cytokine production at single cell level during highly active antiretroviral therapy for HIV-1 infection. J Immunol 1999; 162:3718-26.
37. + T cells as a prognostic marker in vertically HIV-infected pediatric patients. Pediatr Res 2002; 51:740-5.
38. Carbone J, Gil J, Benito JM, et al. Increased levels of activated subsets of CD4 T cells add to the prognostic value of low CD4 T cell counts in a cohort of HIV-infected drug users. AIDS 2000; 14:2823-9.
39. Harper ME, Marselle LM, Gallo RC, et al. Detection of lymphocytes expressing human T-lymphotropic virus type III in lymph nodes and peripheral blood from infected individuals by in situ hybridization. Proc Nad Acad Sci USA 1986; 83:772-6.
40. Ascher MS, Sheppard HW. AIDS as immune system activation: a model for pathogenesis. Clin Exp Immunol 1988; 73:165-7.
41. Meyaard L, Otto SA, Jonker RR, et al. Programmed death of T cells in HIV-1 infection. Science 1992; 257:217-9.
42. Ameisen JC, Capron A. Cell dysfunction and depletion in AIDS: the programmed cell death hypothesis. Immunol Today 1991; 12:102-5.
43. Matsuyama T, Kobayashi N, Yamamoto N. Cytokines and HIV infection: is AIDS a tumor necrosis factor disease? AIDS 1991; 5:1405-17.
44. Swingler S, Mann A, Jacque J, et al. HIV-1 Nef mediates lymphocyte chemotaxis and activation by infected macrophages. Nat Med 1999; 5:997-1003.
45. Mikovits JA, Lohrey NC, Schulof R, et al. Activation of infectious virus from latent human immunodeficiency virus infection of monocytes in vivo. J Clin Invest 1992; 90:1486-91.
46. Ott M, Emiliani S, Van Lint C, et al. Immune hyperactivation of HIV-1-infected T cells mediated by Tat and the CD28 pathway. Science 1997; 275:1481-5.
47. Capobianchi MR. Induction of lymphomonocyte activation by HIV-1 glycoprotein gp120: possible role in AIDS pathogenesis. J Biol Regul Homeostat Agents 1996; 10:83-91.
48. Villinger F, Folks TM, Lauro S, et al. Immunological and virological studies of natural SIV infection of disease-resistant nonhuman primates. Immunol Lett 1996;51:59-68.
49. Shattock RJ, Burger D, Dayer JM, et al. Enhanced HIV replication in monocytic cells following engagement of adhesion molecules and contact with stimulated T cells. Res Virol 1996; 147:171-9.
50. + T cells depleted? Proc Natl Acad Sci USA 2002; 99: 15572-7.
51. Havlir D, Strain M, Clerici M, et al. Productive infection maintains a dynamic steady-state of residual viraemia in H1V-1 infected persons treated with suppressive antiretroviral therapy for 5 years. Antivir Ther 2002; 7:S41.
52. + T-cell count gains in patients with 4 years of suppressed viral load on HAART [abstract 480-M]. In: Program and abstracts of the 9th Conference on Retroviruses and Opportunistic Infections (Seattle). Alexandria, VA: Foundation for Retrovirology and Human Health, 2002:234.
53. Giorgi JV, Majchrowicz MA, Johnson TD, et al. Immunologic effects of combined protease inhibitor and reverse transcriptase inhibitor therapy in previously treated chronic HIV-1 infection. AIDS 1998; 12: 1833-44.
54. Hejdeman B, Lenkei R, Leandersson AC, et al. Clinical and immunological benefits from highly active antiretroviral therapy in spite of limited viral load reduction in HIV type 1 infection. AIDS Res Hum Retroviruses 2001; 17:277-86.
55. + T-cell counts [abstract LbOr09]. In: Program and abstracts of the XIV International AIDS Conference (Barcelona). Barcelona, Spain: Prous Science, 2002:22.
56. Smith D, Zaunders J, Kauffman G, et al. Greater suppression of CD8 activation with 4 vs 3 drugs in early stages of primary HIV infection (PHI) despite similar plasma virological decay rates [abstract 61]. In: Program and abstracts of the 1st IAS Conference on HW Pathogenesis and Treatment (Buenos Aires). Buenos Aires, Argentina: International AIDS Society, 2001:101
57. Valdez H, Anthony D, Farukhi F, et al. Immune responses to hepatitis C and non-hepatitis C antigens in hepatitis C virus infected and HIV-1 coinfected patients. AIDS 2000; 14:2239-46.
58. Rizzardi GP, Harari A, Capiluppi B, et al. Treatment of primary HIV-1 infection with cyclosporin A coupled with highly active antiretroviral therapy. J Clin Invest 2002; 109:681-8.
59. Calabrese LH, Lederman MM, Spritzler J, et al. Placebo-controlled trial of cyclosporin-A in HIV-1 disease: implications for solid organ transplantation. J Acquir Immune Defic Syndr 2002; 29:356-62.
60. Phillips A, Wainberg MA, Coates R, et al. Cyclosporine-induced deterioration in patients with AIDS. CMAJ 1989; 140:1456-60.